Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, China; Tianjin Clinical Research Center for Organ Transplantation, Tianjin 300192, China.
Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, China; Tianjin Clinical Research Center for Organ Transplantation, Tianjin 300192, China.
J Pharmacol Sci. 2019 Jul;140(3):218-222. doi: 10.1016/j.jphs.2019.06.011. Epub 2019 Jul 19.
Liver injury is a serious clinical syndrome that characterized by inflammatory response. Engeletin is known to have anti-inflammatory activity. However, the effects of engeletin on liver injury remain unclear. We aimed to assess the protective effect of engeletin on Lipopolysaccharide (LPS)/d-galactosamine (D-gal)-induced liver injury in mice. Engeletin was administered intraperitoneally 1 h before and 12 h after LPS/D-gal treatment. The results showed that engeletin treatment on LPS/D-gal-induced liver injury in mice have a significant protective effect, as confirmed by the attenuation of liver histopathologic changes, MPO activity, and serum AST and ALT levels. At the meanwhile, it also showed that engeletin inhibited the levels of IL-β and TNF-α in serum and liver tissues. Besides, engeletin blocked the activation of NF-κB induced by LPS/D-gal and induced the expression of PPAR-γ in a dose-dependently manner. These findings suggested that engeletin may have a protective effect against liver injury.
肝损伤是一种以炎症反应为特征的严重临床综合征。已知恩格列汀具有抗炎活性。然而，恩格列汀对肝损伤的影响尚不清楚。本研究旨在评估恩格列汀对脂多糖（LPS）/D-半乳糖胺（D-gal）诱导的小鼠肝损伤的保护作用。恩格列汀在 LPS/D-gal 处理前 1 小时和后 12 小时腹腔内给药。结果表明，恩格列汀对 LPS/D-gal 诱导的小鼠肝损伤具有显著的保护作用，肝组织病理学变化、MPO 活性以及血清 AST 和 ALT 水平的降低证实了这一点。同时，它还表明恩格列汀抑制了血清和肝组织中 IL-β 和 TNF-α 的水平。此外，恩格列汀阻断了 LPS/D-gal 诱导的 NF-κB 的激活，并呈剂量依赖性诱导 PPAR-γ 的表达。这些发现表明恩格列汀可能对肝损伤具有保护作用。
